Patent · US Active

Use of histone modifiers to reprogram effector T cells

US12173317B2 · kind B2 · utility

0Cited by

0References

23Claims

0Family size

Assignee

The Board of Regents of the University of Texas System · US

Inventors

Cassian YEE · Seattle, US
Junmei Wang · Baofeng County, CN

Key dates

Filing date	Mar 28, 2019
Grant date	Dec 24, 2024
Priority date	—
Expiry date	Feb 20, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2506/11
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides methods for re-programming effector T cells to a central memory phenotype comprising culturing the effector T cells with a histone deacetylase inhibitor (HDACi) and IL-21. Further provided are methods of treating cancer comprising administering the central memory T cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.